Archives
-
(S)-(+)-Methoprene Workflow for JH Studies
2026-09-07
Build more informative insect endocrine assays with (S)-(+)-Methoprene, a juvenile hormone analog that separates receptor activation from upstream hormone biosynthesis. This workflow connects developmental phenotypes with vitellogenin, ovarian, transcriptomic, and miRNA–mRNA readouts for mechanism-focused research.
-
Ferroptosis Signature Identifies Atorvastatin in HCC
2026-09-05
A 2025 study integrated TCGA transcriptomics, survival modeling, and Connectivity Map screening to develop a four-gene ferroptosis-related prognostic signature for hepatocellular carcinoma. It also identified Atorvastatin as a candidate compound and reported that the drug suppressed HCC cell growth and migration while inducing ferroptosis in cellular and animal models.
-
Minoxidil sulphate for Vascular Research
2026-09-04
Minoxidil sulphate provides a practical way to connect potassium-channel activation with vascular reactivity, renal perfusion, and hair follicle biology. This workflow-focused guide shows how to prepare, benchmark, and troubleshoot the compound while avoiding overinterpretation of channel-subtype effects.
-
Hippocampal Lipids in Postoperative Cognitive Dysfunction
2026-09-04
The reference study combines behavioral phenotyping, spatial mass spectrometry imaging, enzyme mapping, and ultrastructural analysis to define hippocampal lipid changes after cardiopulmonary bypass in rats. Its intervention data implicate altered phospholipase A2 and serine palmitoyltransferase signaling in postoperative cognitive dysfunction and provide a framework for testing lipid-directed mechanisms.
-
2-Hydroxypropyl-β-cyclodextrin Workflow Guide
2026-09-03
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to improve the apparent aqueous solubility of poorly soluble hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. This guide supports pharmaceutical and biochemical formulation workflows, but it does not establish therapeutic efficacy, universal bioavailability improvement, or suitability as a standalone biological reagent.
-
Super-Enhancer Control of KLF6 in Adipogenesis
2026-09-03
Nguyen et al. identify a KLF6-proximal super-enhancer as an important regulatory hub during the differentiation of human adipose-derived stem cells. Their experiments connect PPARγ- and p300-associated enhancer activation, enhancer RNA production, KLF6 induction, and HDAC3-mediated repression of DLK1, providing a mechanistic framework for adipogenic gene control.
-
CTOP for μ-Opioid Receptor Research
2026-09-02
CTOP provides reversible, selective μ-opioid receptor blockade for separating receptor-driven signaling from downstream pain-circuit effects. This guide translates recent mouse findings into practical binding, signaling, and mechanical hypersensitivity workflows with troubleshooting steps for reproducible assay development.
-
Cyclic di-GMP Antitoxin Controls Biofilm Persistence
2026-09-02
The 2024 eLife study identifies cyclic di-GMP as a small-molecule antitoxin that restrains the genotoxic toxin HipH during early biofilm development. By linking adhesion-stage signaling with DNA double-strand breaks, genome instability, and persister formation, the work refines current models of biofilm resilience and antibiotic tolerance.
-
Calpain Inhibitor I, ALLN: Protocol & QC
2026-09-01
Calpain Inhibitor I, ALLN (SKU A2602) provides a DMSO-compatible research tool for modulating calpain I/II and cathepsin B/L activity in apoptosis assays, inflammation research, and ischemia-reperfusion injury models. It is for controlled laboratory experiments only, not for diagnostic, therapeutic, or clinical use, and cellular or animal dosing must be optimized empirically.
-
KN-62 Workflows for CaMKII Research
2026-09-01
Build reproducible CaMKII experiments with KN-62 across calcium signaling, secretion, metabolism, and proliferation models. This workflow emphasizes matched vehicle controls, orthogonal calcium readouts, and practical troubleshooting to separate kinase-dependent effects from general cellular stress.
-
(S)-(+)-Methoprene Research Workflows
2026-08-31
Use (S)-(+)-Methoprene as a stereochemically defined juvenile hormone analog to connect Met signaling with insect development, reproduction, and endocrine-disruption phenotypes. This practical guide emphasizes stage-matched dosing, miRNA–mRNA readouts, solvent control, and troubleshooting for reproducible arthropod assays.
-
GDC-0994: Reading ERK Signaling in Context
2026-08-31
GDC-0994 is a selective ERK1/2 inhibitor for dissecting how MAP kinase signaling connects with cancer phenotypes and cholestatic injury. This guide emphasizes causal assay design, model boundaries, and interpretation beyond a simple phospho-ERK readout.
-
GW 6471: PPARα Antagonist Workflows
2026-08-30
GW 6471 provides a reversible pharmacological way to test whether PPARα drives lipid disruption, hepatotoxicity, or metabolic phenotypes. This guide translates recent zebrafish toxicology findings into practical workflows for cellular metabolism research, lipid homeostasis studies, and PPARα-related disease modeling.
-
Sumatriptan as an Anti-Inflammatory Agent
2026-08-29
This systematic review reframes sumatriptan, traditionally used for acute migraine and cluster headache, as a candidate modulator of inflammation through 5-HT1B/1D signaling, nitric oxide pathways, cytokine regulation, caspase activity, and CGRP release. Its practical value lies in organizing diverse preclinical evidence while highlighting the need to distinguish mechanistic promise from clinical validation.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-08-28
The reference study identifies SMYD2 as a pharmacologically actionable regulator of cisplatin-induced chronic kidney disease, linking its increased expression with renal fibrosis, epithelial–mesenchymal transition, and inflammation. Using AZ505 and LLY507 in disease-model and tubular-cell experiments, the authors show that SMYD2 inhibition improves renal injury-associated phenotypes and modulates Smad3, STAT3, and Smad7 signaling.